Compare Stocks → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABEONASDAQ:AUGXNASDAQ:RZLTNYSE:VOR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$4.38+4.0%$5.57$2.83▼$9.01$180.40M1.59555,900 shs443,000 shsAUGXAugmedix$0.92-8.1%$2.71$0.90▼$6.25$44.96M0.03578,720 shs816,500 shsRZLTRezolute$4.03-2.9%$2.89$0.72▼$4.40$161.72M1.29445,272 shs265,700 shsVORVor Biopharma$1.35+0.7%$1.83$1.25▼$5.70$92.15M-0.23288,583 shs244,500 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics0.00%+7.88%-4.78%-43.92%+32.33%AUGXAugmedix0.00%-19.46%-66.12%-78.99%+91,809,900.00%RZLTRezolute0.00%+13.20%+21.75%+109.90%+95.63%VORVor Biopharma0.00%-13.18%-25.00%-41.30%-72.16%This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics4.3345 of 5 stars3.53.00.04.52.13.30.6AUGXAugmedix2.2515 of 5 stars3.33.00.00.02.63.30.0RZLTRezolute3.6104 of 5 stars3.54.00.00.04.05.00.0VORVor Biopharma3.2693 of 5 stars4.50.00.00.03.51.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics3.00Buy$21.00379.45% UpsideAUGXAugmedix2.67Moderate Buy$3.88322.07% UpsideRZLTRezolute3.00Buy$8.80118.36% UpsideVORVor Biopharma3.00Buy$12.50825.93% UpsideCurrent Analyst RatingsLatest VOR, AUGX, ABEO, and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2024ABEOAbeona TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.005/22/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.005/16/2024ABEOAbeona TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$28.00 ➝ $21.005/16/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.005/14/2024AUGXAugmedixLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $3.505/14/2024AUGXAugmedixMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$5.00 ➝ $5.005/14/2024AUGXAugmedixEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline$5.00 ➝ $1.505/13/2024VORVor BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$12.005/13/2024VORVor BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00 ➝ $10.005/10/2024VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.004/23/2024ABEOAbeona TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$36.00(Data available from 6/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M51.54N/AN/A($0.22) per share-19.91AUGXAugmedix$44.85M1.00N/AN/A$0.36 per share2.55RZLTRezoluteN/AN/AN/AN/A$1.77 per shareN/AVORVor BiopharmaN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$3.20N/AN/AN/AN/A-543.60%-78.51%8/13/2024 (Estimated)AUGXAugmedix-$19.17M-$0.43N/A∞N/A-41.95%-178.34%-38.74%8/5/2024 (Estimated)RZLTRezolute-$51.79M-$1.14N/AN/AN/AN/A-60.90%-54.58%9/12/2024 (Estimated)VORVor BiopharmaN/A-$1.78N/AN/AN/AN/AN/AN/A8/8/2024 (Estimated)Latest VOR, AUGX, ABEO, and RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024VORVor Biopharma-$0.37-$0.45-$0.08-$0.45N/AN/A3/20/2024Q4 2023VORVor Biopharma-$0.49-$0.39+$0.10-$0.39N/AN/A3/18/2024Q4 2023ABEOAbeona Therapeutics-$0.51-$0.64-$0.13-$0.64N/AN/A3/18/2024Q4 2023AUGXAugmedixN/A-$0.09-$0.09-$0.09$12.30 million$12.68 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AAUGXAugmedixN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona TherapeuticsN/A5.615.61AUGXAugmedix0.732.042.04RZLTRezoluteN/A11.8211.82VORVor BiopharmaN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%AUGXAugmedix87.11%RZLTRezolute82.97%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.30%AUGXAugmedix10.97%RZLTRezolute20.80%VORVor Biopharma4.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A41.19 million39.00 millionOptionableAUGXAugmedix1,43048.97 million43.60 millionOptionableRZLTRezolute5740.13 million31.79 millionNot OptionableVORVor Biopharma16868.26 million65.05 millionNot OptionableVOR, AUGX, ABEO, and RZLT HeadlinesRecent News About These CompaniesMay 28, 2024 | finanznachrichten.deBio-Thera Solutions, Ltd: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UKMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vor Biopharma Amid Promising Clinical Trials and Market Potential ExpansionMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: Vor Biopharma’s Clinical and Financial FortitudeMay 13, 2024 | marketbeat.comVor Biopharma (NYSE:VOR) Given "Market Outperform" Rating at JMP SecuritiesMay 11, 2024 | markets.businessinsider.comSilvan Tuerkcan Reaffirms Buy Rating for Vor Biopharma Citing Clinical Progress and Expanding Market PotentialMay 10, 2024 | markets.businessinsider.comPromising Clinical Trials and Stable Financial Outlook Bolster Buy Rating for Vor BiopharmaMay 10, 2024 | marketbeat.comVor Biopharma (NYSE:VOR) Receives Outperform Rating from WedbushMay 9, 2024 | msn.comVOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024May 9, 2024 | globenewswire.comVor Bio Reports First Quarter 2024 Financial Results and Provides Company UpdateMay 6, 2024 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesMay 3, 2024 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | globenewswire.comVor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of DirectorsApril 23, 2024 | pharmaceutical-technology.comPuretech Health gets grant for treatment of acute myeloid leukemia using genetically engineered cellsApril 20, 2024 | joplinglobe.comTriLink BioTechnologies® kündigt neue Anlage in San Diego zur mRNA-Produktion von Arzneimittelwirkstoffen in der Spätphase anApril 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vor Biopharma on Clinical Progress and Market PotentialApril 4, 2024 | labiotech.euSeven diseases CRISPR technology could cureApril 4, 2024 | zacks.comWhy You Shouldn't Bet Against Vor Biopharma (VOR) StockApril 1, 2024 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesMarch 29, 2024 | finance.yahoo.comHere's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn SituationMarch 28, 2024 | investorplace.comThe Penny Stock A-List: 7 High-Profile Companies on the Verge of GreatnessMarch 26, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)New MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks You Can Buy Before They Become BigMay 6, 2024 8:00 AMView 3 Value Stocks You Can Buy Before They Become Big3 Stocks Nancy Pelosi Has Been BuyingMay 10, 2024 8:35 AMView 3 Stocks Nancy Pelosi Has Been Buying3 Affordable Stocks That Won’t Stay Down Much LongerMay 13, 2024 9:12 AMView 3 Affordable Stocks That Won’t Stay Down Much LongerThese 2 Retail Traders Favorites are Nearing Major BreakoutsMay 24, 2024 8:30 AMView These 2 Retail Traders Favorites are Nearing Major BreakoutsSportradar Rides the Sports Betting Trend From Behind the CurtainMay 22, 2024 6:10 AMView Sportradar Rides the Sports Betting Trend From Behind the CurtainAll HeadlinesCompany DescriptionsAbeona TherapeuticsNASDAQ:ABEOAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.AugmedixNASDAQ:AUGXAugmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.RezoluteNASDAQ:RZLTRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Vor BiopharmaNYSE:VORVor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.